Curaleaf Holdings Inc. falsely advertises its cannabis products as safe and capable of easing a variety of mental health issues despite widespread scientific evidence to the contrary, a proposed class action said.
The company’s websites “are shrewdly and deceptively curated to resemble health care companies’ and project the authority of science and medicine,” according to the complaint filed Monday in the US District Court for the District of Connecticut.
A spokesperson for Curaleaf, one of the largest cannabis companies by market share, said that the “claims appear to be brought by attorneys linked with prohibitionist groups that reject—out of hand—the ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.